Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupFRA:C1P 78 Return-on-Tangible-Equity is 28.19% as of Dec. 2025, which is 3% above its 10-year median of 27.35. GuruFocus rates FRA:C1P with a GF Score™ of 78/100 and a GF Value™ of €0.92 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 899 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 85.43% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Consun Pharmaceutical Group's annualized net income for the quarter that ended in Dec. 2025 was €140.6 Mil. Consun Pharmaceutical Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €498.8 Mil. Therefore, Consun Pharmaceutical Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 28.19%.
The historical rank and industry rank for Consun Pharmaceutical Group's Return-on-Tangible-Equity or its related term are showing as below:
FRA:C1P'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 5.5 Med: 27.35 Max: 42.49
Current: 27.29
During the past 13 years, Consun Pharmaceutical Group's highest Return-on-Tangible-Equity was 42.49%. The lowest was 5.50%. And the median was 27.35%.
FRA:C1P's Return-on-Tangible-Equity is ranked better than 85.43% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs FRA:C1P: 27.29
Consun Pharmaceutical Group (FRA:C1P) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Consun Pharmaceutical Group Return-on-Tangible-Equity Related Terms
Consun Pharmaceutical Group Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group Return-on-Tangible-Equity Chart
FRA:C1P vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 28.19% mean?
Consun Pharmaceutical Group (FRA:C1P) has a Return-on-Tangible-Equity of 28.19% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Consun Pharmaceutical Group and its competitors. This is near median its historical median of 27.35. Over the past decade, Consun Pharmaceutical Group's Return-on-Tangible-Equity has ranged from 5.50 to 42.49. According to the industry distribution chart, Consun Pharmaceutical Group ranks #131 out of 899 companies in the Drug Manufacturers industry, placing it in the top 14.6%.
Is Consun Pharmaceutical Group's Return-on-Tangible-Equity too high?
Consun Pharmaceutical Group's current Return-on-Tangible-Equity of 28.19% is near median its 10-year median of 27.35. Over the past 10 years, this metric has ranged from a low of 5.50 to a high of 42.49. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.95. Consun Pharmaceutical Group's value of 28.19% is 254.6% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #131 out of 899 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #131 out of 899 companies for Return-on-Tangible-Equity. This places Consun Pharmaceutical Group in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.95. Consun Pharmaceutical Group's value of 28.19% is 254.6% above this benchmark. Historically, Consun Pharmaceutical Group's own Return-on-Tangible-Equity has ranged from 5.50 to 42.49 over the past decade. While the company's 10-year median is 27.35 vs. the industry median of 7.95, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.95, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Return-on-Tangible-Equity of 28.19% is 254.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Return-on-Tangible-Equity is 28.19%, which is near median its own 10-year median of 27.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (FRA:C1P) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.92, compared to a current price of €1.50 — trading 63% above its estimated fair value. The current Return-on-Tangible-Equity is 28.19%, which is near median its 10-year median of 27.35 and 254.6% above the Drug Manufacturers industry median of 7.95. Consun Pharmaceutical Group's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Consun Pharmaceutical Group (FRA:C1P), the current Return-on-Tangible-Equity is 28.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (FRA:C1P) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.50 is trading 63% above its estimated GF Value™ of €0.92.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for FRA:C1P:
Return-on-Tangible-Equity: 28.19% (near median its 10-year median of 27.35)
GF Value™: €0.92 vs. price of €1.50 (63% above fair value)
Industry Position: 254.6% above the Drug Manufacturers median (#131 of 899)
No single metric tells the full story. See the FRA:C1P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
78GF Score
Get the complete analysis for FRA:C1P
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C1P has been successfully added to your 
